glp-1 moa Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Video: Non-insulin injectable antidiabetic drugs
Description
This unique approach could lead to more comprehensive metabolic benefits and improved weight management outcomes
2024;403(10434):e2131
Hemoglobin A1c (HbA1c): What to know if you have diabetes or prediabetes or are at risk for these conditions
Notably, the observed variability in efficacy between agents, particularly in the early phases of treatment, emphasizes the importance of individualized therapeutic strategies, tailored to specific clinical goals, baseline metabolic profiles, and patient preferences
